Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 54,972 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Patient Clear all
Recruiting Phase 1Phase 2 Interventional

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

NCT06810544
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor, Non-Small Cell Adenocarcinoma, Lung Cancer, Brain Tumor
Interventions
TNG456, abemaciclib
Drug
Lead sponsor
Tango Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Scottsdale, Arizona • Irvine, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 10, 2026, 2:28 PM EST
Completed Phase 1 Interventional

A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

NCT02922764
View directory record Official record
Conditions
Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma
Interventions
RGX-104, Ipilimumab, Docetaxel, Pembrolizumab, Carboplatin, Pemetrexed
Drug
Lead sponsor
Inspirna, Inc.
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
21
States / cities
Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Nov 10, 2026, 2:28 PM EST
Completed Phase 2 Interventional Results available

Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL

NCT01145209
View directory record Official record
Conditions
Small Lymphocytic Lymphoma, CLL (Chronic Lymphocytic Leukemia)
Interventions
Fludarabine Phosphate, Ofatumumab, Cyclophosphamide
Drug · Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Nov 10, 2026, 2:28 PM EST
Recruiting Not applicable Interventional

Effects of Ketosis on Brain Function in Patients With T1DM

NCT04219709
View directory record Official record
Conditions
Type1diabetes
Interventions
Very low carbohydrate diet, Standard carbohydrate diet
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Nov 10, 2026, 2:28 PM EST
Completed Phase 1Phase 2 Interventional

Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer

NCT00083109
View directory record Official record
Conditions
Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Interventions
Fluorouracil, Pharmacological Study, Suramin
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 25, 2015 · Synced Nov 10, 2026, 2:28 PM EST
Completed Phase 1 Interventional Results available

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

NCT01001299
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Drug cocktail, RO5185426
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Nov 10, 2026, 2:28 PM EST
Not listed Not applicable Interventional

Accuracy of the Thoracic Epidural Catheter Insertion Confirmed by Fluoroscopic Imaging

NCT01764932
View directory record Official record
Conditions
Patients Undergoing Thoracic Surgery, Patients Undergoing Upper Abdominal Surgery
Interventions
Fluoroscopic imaging
Procedure
Lead sponsor
Chicago Anesthesia Pain Specialists
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Nov 10, 2026, 2:28 PM EST
Completed Phase 2 Interventional

Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer

NCT00046787
View directory record Official record
Conditions
SCLC, Carcinoma, Small Cell
Interventions
OSI-211 (Liposomal Lurtotecan)
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
4
States / cities
Tucson, Arizona • Denver, Colorado • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2011 · Synced Nov 10, 2026, 2:28 PM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluating the Efficacy of PECS II Block Versus Axillary Ring Block in Rotator Cuff Repair Patients

NCT04930393
View directory record Official record
Conditions
Shoulder Pain
Interventions
Nerve Block - either PECS II or axillary ring
Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Nov 10, 2026, 2:28 PM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

ED2PrEP - Patient Focused, Low-burden Strategies for PrEP Uptake Among Emergency Departments

NCT05588193
View directory record Official record
Conditions
HIV
Interventions
PVO, TSH
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
1,560 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Nov 10, 2026, 2:28 PM EST
Completed Phase 2Phase 3 Interventional

Deep Brain Stimulation in Treating Patients With Dystonia

NCT00004421
View directory record Official record
Conditions
Dystonia
Interventions
implanted pulse generator
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Nov 10, 2026, 2:28 PM EST
Completed Not applicable Interventional

Evaluating Patient Participation in Phase I Clinical Trials

NCT00043030
View directory record Official record
Conditions
Psychosocial Effects of Cancer and Its Treatment, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
psychosocial assessment and care
Procedure
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Nov 10, 2026, 2:28 PM EST
Completed No phase listed Observational

Evaluation of a Personalized Care Management Program for High Hospital Utilizers

NCT04727567
View directory record Official record
Conditions
Comorbidities and Coexisting Conditions
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Nov 10, 2026, 2:28 PM EST
Completed Phase 2 Interventional Results available

Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy

NCT02353728
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Nilotinib
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Nov 10, 2026, 2:28 PM EST
Terminated Phase 3 Interventional Results available

Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT02785900
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
33A, placebo, azacitidine, decitabine
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
40
States / cities
Little Rock, Arkansas • Duarte, California • San Francisco, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Nov 10, 2026, 2:28 PM EST
Not listed Phase 1 Interventional

Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer

NCT03638765
View directory record Official record
Conditions
Brain Metastases, Lung Cancer Metastatic, Breast Cancer Metastatic
Interventions
DCVax-Direct
Biological
Lead sponsor
Northwest Biotherapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Nov 10, 2026, 2:28 PM EST
Recruiting Not applicable Interventional

A Pilot Study to Evaluate the Effectiveness of Focused Massage on Pain, Mobility, and Quality of Life During Radiation Treatment for Patients With Breast Cancer

NCT07447700
View directory record Official record
Conditions
Breast Cancer, Radiation Therapy Patient
Interventions
upper body massage
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 10, 2026, 2:28 PM EST
Completed Not applicable Interventional

Quitline Use in Surgical Patients

NCT00656500
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Standard brief advice, Quitline intervention
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Nov 10, 2026, 2:28 PM EST
Terminated Phase 2 Interventional Results available

Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC

NCT03719300
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions
inodiftagene vixteplasmid
Drug
Lead sponsor
Anchiano Therapeutics Israel Ltd.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
48
States / cities
Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Nov 10, 2026, 2:28 PM EST
Suspended Phase 2 Interventional

Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL

NCT03097107
View directory record Official record
Conditions
Dyslipidemias
Interventions
Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Saroglitazar Magnesium 4 mg, Placebo
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
33
States / cities
Huntsville, Alabama • Encinitas, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Nov 10, 2026, 2:28 PM EST
Completed Not applicable Interventional

Golf Instruction Versus Tai Chi for People With Parkinson's Disease

NCT03563807
View directory record Official record
Conditions
Parkinson Disease, Movement Disorders, Neuro-Degenerative Disease
Interventions
Golf Instruction, Tai Chi Class
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Nov 10, 2026, 2:28 PM EST
Completed Phase 4 Interventional

Evaluation of the SafeR Mode in Patients With a Dual Chamber Pacemaker Indication

NCT00562107
View directory record Official record
Conditions
Assess the Benefits From the AAISafeR/SafeR Algorithm of Symphony 2550 or REPLYTM DR in a Wide Range of Pacemaker Patients.
Interventions
Symphony DR 2550 and REPLY DR cardiac pacemakers
Device
Lead sponsor
LivaNova
Industry
Eligibility
Not listed
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Nov 10, 2026, 2:28 PM EST
Terminated Phase 2 Interventional Results available

Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer

NCT01871571
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions
bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 10, 2026, 2:28 PM EST
Completed Phase 2 Interventional Results available

Dose Finding Study to Treat High Phosphate Levels in the Blood.

NCT02081534
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
AZD1722, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 85 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
16
States / cities
Downey, California • Los Angeles, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2020 · Synced Nov 10, 2026, 2:28 PM EST